LNTH Stock Overview
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LNTH from our risk checks.
Lantheus Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$65.20 |
| 52 Week High | US$100.85 |
| 52 Week Low | US$50.20 |
| Beta | 0.54 |
| 1 Month Change | 10.98% |
| 3 Month Change | 23.30% |
| 1 Year Change | -23.47% |
| 3 Year Change | 177.21% |
| 5 Year Change | 159.76% |
| Change since IPO | 914.00% |
Recent News & Updates
Recent updates
Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital
Apr 12
Lantheus Holdings: Undervalued With A Good Outlook
Feb 28Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Feb 24Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly
Feb 08Market Participants Recognise Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Earnings
Jan 03Return Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Appealing
Dec 16A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)
Nov 28Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?
Nov 09Returns At Lantheus Holdings (NASDAQ:LNTH) Appear To Be Weighed Down
Sep 04Calculating The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)
Aug 09Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?
Jul 22Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively
May 29Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly
Apr 16Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal
Feb 27An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued
Jan 16Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt
Dec 24Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively
Oct 31Does This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?
Oct 04Looking In On Lantheus Holdings
Sep 14Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent
Aug 25Lantheus Non-GAAP EPS of $0.89 beats by $0.19, revenue of $223.72M beats by $19.21M
Aug 04Lantheus Holdings (NASDAQ:LNTH) May Have Issues Allocating Its Capital
Jul 22Lantheus Holdings Rules The Medical Diagnostics Business World
Jul 06We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease
Jun 25There Are Reasons To Feel Uneasy About Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital
Apr 22Lantheus: Managing A Winner
Apr 07Shareholder Returns
| LNTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.6% | 1.6% | 1.0% |
| 1Y | -23.5% | -1.4% | 21.9% |
Return vs Industry: LNTH underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: LNTH underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| LNTH volatility | |
|---|---|
| LNTH Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LNTH has not had significant price volatility in the past 3 months.
Volatility Over Time: LNTH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 834 | Brian Markison | www.lantheus.com |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.
Lantheus Holdings, Inc. Fundamentals Summary
| LNTH fundamental statistics | |
|---|---|
| Market cap | US$4.47b |
| Earnings (TTM) | US$326.66m |
| Revenue (TTM) | US$1.30b |
13.7x
P/E Ratio3.4x
P/S RatioIs LNTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LNTH income statement (TTM) | |
|---|---|
| Revenue | US$1.30b |
| Cost of Revenue | US$470.49m |
| Gross Profit | US$825.94m |
| Other Expenses | US$499.28m |
| Earnings | US$326.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 4.77 |
| Gross Margin | 63.71% |
| Net Profit Margin | 25.20% |
| Debt/Equity Ratio | 68.8% |
How did LNTH perform over the long term?
See historical performance and comparison